Lakefront Biotherapeutics LKFT
$33.31 −$0.08 (-0.24%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $33.31 0.00%
Open$33.61
Prev close$33.39
Day range$33.25 – $33.85
Volume162.5K
Market cap$2.18B
P/E (TTM)2.5
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026 · reported in EUR
Revenue€7.58M-89.4% YoY
Operating profit-€41.17M+1.2% YoY
Net profit-€2.67M+98.7% YoY
Diluted EPS-€0.04+98.7% YoY
Free cash flow-€35.45M+45.8% YoY
Operating cash flow-€35.30M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin98.1%
Operating margin65.8%
Net margin85.9%
Return on equity28.0%
Return on assets23.4%
Return on invested capital28.0%
Current ratio46.52
Liabilities / assets1.9%
Cash & investments€2.18B
Total debt€1.83M
Net cash (debt)€2.18B
Where the revenue comes from
Quarter 2025/FY
By region
This company reports in its own local currency, not U.S. dollars. Every figure below is labeled with its real currency, not automatically converted.
Income statement
| Line item | 2026 Q3 (EUR) |
2026 Q2 (EUR) |
2026 Q1 (EUR) |
2025 ANNUAL (EUR) |
2025 Q4 (EUR) |
|---|---|---|---|---|---|
| Total Revenue as Reported | €7.58M | €12.11M | €6.48M | €1.11B | €900.82M |
| Total Operating Revenue | €7.58M | €12.11M | €6.48M | €1.11B | €900.82M |
| Cost of Revenue | €3.68M | €9.15M | €4.80M | €29.74M | €455,000.00 |
| Gross Profit | €3.90M | €2.97M | €1.68M | €1.08B | €900.37M |
| Operating Expense | €45.07M | €46.48M | €65.39M | €581.12M | €141.57M |
| Selling and Admin Expenses | €33.59M | €7.51M | €35.51M | €111.96M | €2.94M |
| Research & Development | €26.01M | €25.52M | €30.96M | €459.42M | €107.51M |
| Other Operating Expenses | -€13.09M | €12.00M | -€1.08M | €254,000.00 | €21.63M |
| Operating Profit | -€41.17M | -€43.51M | -€63.70M | €501.39M | €758.80M |
| Net Non-Operating Interest Income (Expense) | €11.07M | €12.65M | €13.42M | €45.19M | €14.75M |
| Total Other Finance Costs | -€37.24M | -€35,000.00 | €137,000.00 | -€1.07M | €29.38M |
| Other Income (Expense) | €21.92M | €32.88M | €64.24M | -€245.71M | €9.61M |
| Gain on Sale of Security | €21.92M | €32.88M | €64.24M | -€39.36M | €11.21M |
| Pretax Profit | -€8.18M | €2.01M | €13.96M | €300.87M | €783.16M |
| Tax | €105,000.00 | €70,000.00 | €70,000.00 | -€18.62M | €666,000.00 |
| Net Profit | -€2.67M | €2.11M | €14.49M | €320.88M | €782.15M |
| Profit from Continuing Operations | -€8.29M | €1.94M | €13.89M | €319.49M | €782.49M |
| Net Income from Discontinuous Operations | €5.62M | €165,000.00 | €606,000.00 | €1.39M | -€343,000.00 |
| Net Income to Parent Company | -€2.67M | €2.11M | €14.49M | €320.88M | €782.15M |
| Net Income to Common Stockholders | -€2.67M | €2.11M | €14.49M | €320.88M | €782.15M |
| Basic EPS | -€0.04 | €0.03 | €0.22 | €4.87 | €11.87 |
| Diluted EPS | -€0.04 | €0.03 | €0.22 | €4.87 | €11.87 |
| -Selling & Marketing Expense | – | -€94,000.00 | €2.77M | €1.39M | -€3.01M |
| -General & Admin Expense | – | €7.60M | €32.74M | €110.57M | €5.95M |
| Non-Operating Interest Income | – | €12.74M | €13.56M | €46.34M | – |
| Depreciation & Amortization & Depletion | – | – | – | €9.49M | – |
| -Depreciation & Amortization | – | – | – | €9.49M | – |
| Non-Operating Interest Expense | – | – | – | €2.22M | – |
| Special Income (Charges) | – | – | – | -€206.35M | -€1.60M |
| -Less:Restructuring and Mergern & Acquisition | – | – | – | -€21.76M | – |
| -Less:Impairment of Capital Assets | – | – | – | €228.11M | €23.36M |
Balance sheet
| Line item | 2026 Q3 (EUR) |
2026 Q2 (EUR) |
2026 Q1 (EUR) |
2025 ANNUAL (EUR) |
2025 Q4 (EUR) |
|---|---|---|---|---|---|
| Total Assets | €3.29B | €3.35B | €3.37B | €3.41B | €3.41B |
| Total Current Assets | €2.25B | €2.31B | €3.06B | €3.08B | €3.08B |
| Cash and Cash Equivalents & Short-Term Investments | €2.18B | €2.24B | €2.98B | €3.00B | €3.00B |
| -Cash and Cash Equivalents | €94.66M | €135.95M | €66.81M | €87.87M | €87.87M |
| -Short Term Investments | €2.09B | €2.10B | €2.92B | €2.91B | €2.91B |
| Receivables | €53.34M | €56.30M | €54.03M | €53.20M | €53.20M |
| -Accounts Receivable | €20.62M | €23.70M | €21.74M | €9.57M | €9.57M |
| -Other Receivables | €32.72M | €32.60M | €32.30M | €43.64M | €43.64M |
| Inventory | €4.87M | €8.54M | €17.69M | €22.49M | €22.49M |
| Other Current Assets | €5.69M | €3.96M | €4.08M | – | – |
| Total Non-Current Assets | €1.05B | €1.04B | €311.69M | €327.06M | €327.06M |
| Net PPE | €75.69M | €76.89M | €76.95M | €80.66M | €80.66M |
| Investments and Advances | €74.02M | €73.86M | €47.93M | €46.81M | €46.81M |
| -Long Term Equity Investment | €74.02M | €73.86M | €47.93M | €46.81M | €46.81M |
| Non Current Accounts Receivables | €139.65M | €137.55M | €161.37M | €174.41M | €174.41M |
| Non-Current Note Receivables | €62,000.00 | €62,000.00 | €21.58M | €21.18M | €21.18M |
| Goodwill and Other Intangible Assets | €754.26M | €750.66M | €746,000.00 | €848,000.00 | €848,000.00 |
| -Other Intangible Assets | €754.26M | €750.66M | €746,000.00 | €848,000.00 | €848,000.00 |
| Non-Current Deferred Assets | €99,000.00 | €134,000.00 | €163,000.00 | €195,000.00 | €195,000.00 |
| Other Non-Current Assets | €2.65M | €2.68M | €2.95M | €2.96M | €2.96M |
| Total Liabilities | €61.81M | €87.56M | €119.06M | €170.65M | €170.65M |
| Total Current Liabilities | €48.33M | €70.32M | €100.42M | €152.86M | €152.86M |
| Payables | €45.92M | €67.30M | €96.68M | €33.58M | €33.58M |
| -Accounts Payable | €45.65M | €66.35M | €95.77M | €32.62M | €32.62M |
| -Total Tax Payable | €276,000.00 | €953,000.00 | €912,000.00 | €956,000.00 | €956,000.00 |
| Short-Term Debt and Capital Lease Obligation | €1.27M | €1.59M | €1.58M | €1.73M | €1.73M |
| -Current Capital Lease Obligation | €1.27M | €1.59M | €1.58M | €1.73M | €1.73M |
| Current Provisions | €1.10M | €1.40M | €2.13M | €45.50M | €45.50M |
| Current Deferred Liabilities | €33,000.00 | €33,000.00 | €32,000.00 | €32,000.00 | €32,000.00 |
| Total Non-Current Liabilities | €13.48M | €17.23M | €18.64M | €17.79M | €17.79M |
| Long Term Debt and Capital Lease Obligation | €1.83M | €4.77M | €4.85M | €5.19M | €5.19M |
| -Long Term Capital Lease Obligation | €1.83M | €4.77M | €4.85M | €5.19M | €5.19M |
| Other Non-Current Liabilities | €11.65M | €12.46M | €13.79M | €12.60M | €12.60M |
| Total Equity | €3.23B | €3.26B | €3.25B | €3.24B | €3.24B |
| Stockholders' Equity | €3.23B | €3.26B | €3.25B | €3.24B | €3.24B |
| Capital Stock | €293.94M | €293.94M | €293.94M | €293.94M | €293.94M |
| -Common Stock | €293.94M | €293.94M | €293.94M | €293.94M | €293.94M |
| Additional Paid-In Capital | €2.74B | €2.74B | €2.74B | €2.74B | €2.74B |
| Retained Earnings | €239.37M | €233.96M | €228.33M | €210.58M | €210.58M |
| Less: Treasury Stock | -€42.60M | -€6.08M | – | – | – |
| Gains/Losses Not Affecting Retained Earnings | €5.06M | €4.82M | -€5.89M | -€5.64M | -€5.64M |
| Prepaid Assets | – | – | – | €103,000.00 | €103,000.00 |
| Restricted Cash | – | – | – | €0.00 | €0.00 |
| Current Deferred Assets | – | – | – | €5.61M | €5.61M |
| -Gross PPE | – | – | – | €140.28M | €140.28M |
| -Accumulated Depreciation | – | – | – | -€59.62M | -€59.62M |
| Non-Current Prepaid Assets | – | – | – | €0.00 | €0.00 |
| -Goodwill | – | – | – | €0.00 | €0.00 |
| Current Accrued Expenses | – | – | – | €20,000.00 | €20,000.00 |
| Other Current Liabilities | – | – | – | €38.90M | €38.90M |
| Non-Current Deferred Liabilities | – | – | – | €0.00 | €0.00 |
| Employee Benefits | – | – | – | €0.00 | €0.00 |
Cash flow
| Line item | 2026 Q3 (EUR) |
2026 Q2 (EUR) |
2026 Q1 (EUR) |
2025 ANNUAL (EUR) |
2025 Q4 (EUR) |
|---|---|---|---|---|---|
| Operating Cash Flow | -€35.30M | -€34.09M | -€82.75M | -€257.46M | -€47.46M |
| Net cash flow from continuing operations | -€35.30M | -€34.09M | -€82.75M | -€257.46M | -€47.46M |
| Net Income from Continuing Operations | -€2.67M | €2.11M | €14.49M | €320.88M | €782.15M |
| Other Non-Cash Items | -€125.98M | €47.63M | -€73.66M | -€100.84M | -€154.73M |
| Change in Working Capital | €41.45M | -€7.52M | -€35.44M | -€876.57M | -€813.79M |
| -Change In Other Working Capital | €42.59M | -€8.66M | -€35.44M | -€1.03B | -€963.04M |
| Net cash flow from investing | €32.41M | €101.42M | €61.50M | €288.81M | €72.62M |
| Net Cash Flow from Continuing Investing Activities | €32.41M | €101.42M | €61.50M | €288.81M | €72.62M |
| Net PPE Purchase and Sale | €123,000.00 | €1.05M | €1.19M | -€13.24M | -€1.22M |
| Net Intangibles Purchase and Sale | €0.00 | €0.00 | €0.00 | -€155,000.00 | €0.00 |
| Net Business Purchase and Sale | -€4.81M | -€731.75M | €2.34M | €19.43M | €1.62M |
| Net Investment Purchase and Sale | €34.92M | €779.62M | €57.96M | €242.33M | €67.15M |
| Net Other Investing Changes | €0.00 | – | – | -€20.00M | €0.00 |
| Financing Cash Flow | -€38.47M | -€3.94M | -€510,000.00 | -€3.27M | -€405,000.00 |
| Net Cash Flow from Continuing Financing Activities | -€38.47M | -€3.94M | -€510,000.00 | -€3.27M | -€405,000.00 |
| Net Issuance Payments Of Debt | -€565,000.00 | -€1.07M | -€510,000.00 | -€3.27M | -€405,000.00 |
| Net Common Stock Issuance | -€37.91M | – | – | – | – |
| Ending Cash Balance | €94.66M | €135.95M | €66.81M | €87.87M | €87.87M |
| Net Change in Cash | -€41.36M | €63.39M | -€21.76M | €28.09M | €24.76M |
| Beginning Cash Balance | €135.95M | €66.81M | €87.87M | €64.24M | €64.46M |
| Effect of Exchange Rate Changes | €62,000.00 | €5.76M | €700,000.00 | -€4.46M | -€1.35M |
| Free Cash Flow | -€35.45M | -€34.12M | -€82.87M | -€271.32M | -€49.07M |
| Gain/Loss from Continuing Operations | – | – | – | €17.68M | – |
| Depreciation & Depletion & Amortization | – | – | – | €55.88M | – |
| Deferred Tax | – | – | – | -€18.14M | – |
| -Change in Receivables | – | – | – | €86.59M | – |
| -Change in Inventory | – | – | – | €28.85M | – |
| -Change in Other Current Liabilities | – | – | – | €33.81M | – |
No comments yet — be the first to weigh in on LKFT.
Sign in to join the discussion.